Oct
23rd
Thu
23rd
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Conclusions: Patients with a colorectal tumor bearing mutatedK-ras did not benefit from cetuximab, whereas patients witha tumor bearing wild-type K-ras did benefit from cetuximab (overall survival median, 9.5 vs. 4.8 months).The mutation status of the K-ras gene had no influence on survivalamong patients treated with best supportive care alone.
[NEJM 2008]
